Eurofins Genoma introduces GeneSafeTM – the first non-invasive prenatal test that screens for single-gene disorders

Eurofins Genoma Srl (“Genoma”), a wholly-owned subsidiary of Eurofins Scientific (EUFI.PA), is proud to introduce GeneSafe^TM, the first non-invasive prenatal test (NIPT) that screens for both de novo (gene mutations that are not inherited) and inherited single-gene disorders. Eurofins Genoma, one of the leading specialty diagnostics testing providers in Italy, is a pioneer of NIPT and leads the industry in innovative diagnostic tests in oncology.

Currently, NIPTs available in the market only screen for aneuploidies and microdeletions. Genoma’s own PrenatalSafe® Karyo also screens for rare aneuploidies and segmental chromosome imbalances in every chromosome in the fetal genome. GeneSafe^TM goes much further, identifying fetal conditions that could be missed by traditional prenatal testing. It detects over 40 severe genetic disorders that may occur in the absence of any family history of the condition. Furthermore, GeneSafe^TM is now the first NIPT to detect disorders with an increased prevalence associated with advanced paternal age. Nowadays, later-stage parenthood is increasingly common, particularly in developed countries.

GeneSafe^TM is simple, requiring only a small blood sample, and completely safe, posing no risks for the fetus. In addition, it is extremely reliable and very fast, with a turnaround time of only 10 days. It works as a complementary screen to traditional NIPT, providing a more complete picture of the risk of a pregnancy being affected by a genetic disorder. Eurofins Genoma will be launching GeneSafe^TM in the upcoming weeks and is constantly working to further expand the number of genetic disorders that their tests are able to detect.

Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Genoma, in June of this year, has been very beneficial in expanding Eurofins’ testing portfolio in the specialty clinical diagnostics market. Their long history of innovation in genetic testing has, once again, been reinforced with the introduction of GeneSafe^TM. This new test, while providing previously unavailable insights to expecting mothers and medical practitioners working with Genoma, will also be made available to those served by Eurofins’ clinical diagnostics companies around the world, including Biomnis, Megalab, Lifecodexx as well as Eurofins’ subsidiaries in Asia. This is a clear demonstration of the benefits that Eurofins’ growing network of clinical genetics laboratories can provide to patients and healthcare professionals globally.”

For more information, please visit www.eurofins.com or contact:

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 375 laboratories across 41 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.